Investigation into Argenx SE Sparks Concern Among Investors Post FDA Alert

Investigation into Argenx SE: A Concern for Investors

Recently, the well-respected Pomerantz Law Firm has announced they are looking into claims on behalf of investors associated with argenx SE, a biotech firm.

On June 30, 2025, the U.S. Food and Drug Administration (FDA) released a troubling alert about argenx’s product, Vyvgart Hytrulo, which treats a rare autoimmune condition. According to the FDA, there are indications that the treatment may cause significant health risks, particularly a serious worsening of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). This alarming report prompted Pomerantz to investigate whether argenx and selected corporate officers may have engaged in securities fraud or other unethical business activities.

Following the FDA's announcement, the stock price of argenx’s American Depositary Shares (ADS) experienced a substantial drop — $8.92 to close at $551.22 per ADS. This reflects a 1.59% decrease in just a single day, indicating investor anxiety and the market's reaction to the news. Those who invested in argenx are naturally concerned about the implications of the FDA's alert, and whether they could potentially recover damages if they incurred losses as a result of the company's practices.

For investors interested in more information about the investigation and possibly joining a class action lawsuit, Pomerantz has provided contact information for Danielle Peyton, who can be reached via email or phone.

Pomerantz LLP has established a prominent reputation as a leader in corporate and securities class litigation. Since its establishment over 85 years ago by Abraham L. Pomerantz, well-known as a pioneer in the realm of class action lawsuits, the firm has remained committed to protecting the rights of investors subjected to securities fraud and other corporate misconduct. With notable offices in major cities such as New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, Pomerantz boasts a track record of recovering substantial settlements on behalf of their clients.

As the investigation unfolds, it remains to be seen how this situation will evolve and what further actions may be taken both by the firm and by regulatory authorities. Investors are advised to stay abreast of updates regarding these developments as they might significantly impact the future performance of argenx SE’s stock.

For continued updates and further inquiries, interested parties should consider following Pomerantz on their official website, where the firm regularly publishes news releases and investigations involving various companies in the market.

Given the high stakes involved in such legal matters and the potential repercussions for those with financial ties to argenx SE, remaining informed is vital. Investors should consider not only the immediate impacts of the FDA's alert but also the broader implications for the biotechnology industry at large as it grapples with ongoing scrutiny and regulatory oversight.